6EUY image
Entry Detail
PDB ID:
6EUY
Title:
Structure of the midlink and cap-binding domains of influenza A polymerase PB2 subunit with a bound azaindazole cap-binding inhibitor
Biological Source:
PDB Version:
Deposition Date:
2017-10-31
Release Date:
2017-12-13
Method Details:
Experimental Method:
Resolution:
3.00 Å
R-Value Free:
0.26
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Polymerase basic protein 2
Chain IDs:A, B, C
Chain Length:290
Number of Molecules:3
Biological Source:Influenza A virus (A/Victoria/3/1975(H3N2))
Primary Citation
Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.
Nucleic Acids Res. 46 956 971 (2018)
PMID: 29202182 DOI: 10.1093/nar/gkx1210

Abstact

Influenza polymerase uses short capped primers snatched from nascent Pol II transcripts to initiate transcription of viral mRNAs. Here we describe crystal structures of influenza A and B polymerase bound to a capped primer in a configuration consistent with transcription initiation ('priming state') and show by functional assays that conserved residues from both the PB2 midlink and cap-binding domains are important for positioning the capped RNA. In particular, mutation of PB2 Arg264, which interacts with the triphosphate linkage in the cap, significantly and specifically decreases cap-dependent transcription. We also compare the configuration of the midlink and cap-binding domains in the priming state with their very different relative arrangement (called the 'apo' state) in structures where the potent cap-binding inhibitor VX-787, or a close analogue, is bound. In the 'apo' state the inhibitor makes additional interactions to the midlink domain that increases its affinity beyond that to the cap-binding domain alone. The comparison suggests that the mechanism of resistance of certain mutations that allow virus to escape from VX-787, notably PB2 N510T, can only be rationalized if VX-787 has a dual mode of action, direct inhibition of capped RNA binding as well as stabilization of the transcriptionally inactive 'apo' state.

Legend

Protein

Chemical

Disease

Primary Citation of related structures